Credit: Celltrion Avtozma, formerly known as CT-P47, is an interleukin-6 receptor antagonist. Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity ...

On March 16, 2026, Celltrion, Inc. announced the U.S. commercial launch of AVTOZMA® (tocilizumab-anoh) SC, a subcutaneous formulation of its tocilizumab biosimilar referencing Roche’s ACTEMRA.

The FDA approval was based on data demonstrating that Tofidence is highly similar to the reference product. The Food and Drug Administration (FDA) has approved Tofidence™ (tocilizumab-bavi), the first ...

On July 2, 2024, Fresenius Kabi (“Fresenius”) announced the immediate availability of TYENNE (tocilizumab-aazg), in a subcutaneous formulation, in the United States. TYENNE, a biosimilar to ACTEMRA ...

– Medicine offers a new option for children living with a rare and severe form of arthritis – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX ...

About half of patients with steroid-dependent polymyalgia rheumatica (PMR) were able to get off steroids altogether when they were started on tocilizumab (Actemra) infusions, which also improved ...

Patients with rheumatoid arthritis (RA) who were treated with tocilizumab (Actemra) had twice the risk of gastrointestinal perforations than those on tumor necrosis factor (TNF) inhibitors, Swedish ...